COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

NCT02404376 · Completed

Last updated 2026-05-28

This clinical trial tested whether a combination of treatments in people experiencing a severe heart attack could reduce the amount of heart muscle damage.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 378 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-03 · est. completion 2020-06

Where 6 sites · Spain

What this study is testing ClinicalTrials.gov NCT02404376 ↗

Description as written by the study sponsor.

Remote ischemic conditioning (RIC) and intravenous exenatide administered immediately before primary angioplasty have been found to limit infarct size in patients with STEMI (ST segment elevation myocardial infarction), but the reduction is limited. This study investigates whether a combination therapy including both therapies is more effective.

Treatments tested

Exenatide Drug

Intravenous administration of Exenatide
Remote Ischemic Conditioning (RIC) Other

Remote ischemic conditioning with a cuff in the arm
Placebo Drug

Intrevenous administration of Placebo

Main thing measured	Myocardial Infarct Size
Sponsor	Hospital Universitari Vall d'Hebron Research Institute
Conditions studied	ST Elevation Acute Myocardial Infarction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02404376 ↗